PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell Metastasis
- Interventions
- Drug: SU011248 (sunitinib)
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT00137423
- Locations
- 🇨🇭
Pfizer Investigational Site, St. Gallen, Switzerland
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00137449
- Locations
- 🇮🇹
Pfizer Investigational Site, Milano, Italy
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 582
- Registration Number
- NCT00137046
- Locations
- 🇲🇽
Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
Phase 3
Completed
- Conditions
- Osteoarthritis,Knee
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00137410
- Locations
- 🇮🇹
Pfizer Investigational Site, Venezia, Italy
Irinotecan Study For Cervical Cancer
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00136955
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.
Phase 3
Completed
- Conditions
- Hypercholesterolemia, FamilialHyperlipidemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 800
- Registration Number
- NCT00136981
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Subcutaneous insulin
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 635
- Registration Number
- NCT00136916
- Locations
- 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT00134147
- Locations
- 🇬🇧
Pfizer Investigational Site, York, United Kingdom
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
Phase 3
Completed
- Conditions
- Coronary DiseaseHyperlipidemiaCoronary Arteriosclerosis
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1100
- Registration Number
- NCT00134173
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Phase 3
Completed
- Conditions
- HypertriglyceridemiaHyperlipoproteinemia Type IV
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00134498
- Locations
- 🇨🇦
Pfizer Investigational Site, Ste-Foy, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath